Illumina, Inc. (NASDAQ:ILMN) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Illumina, Inc. (NASDAQ:ILMN) have earned a consensus recommendation of “Moderate Buy” from the twenty-one analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation, ten have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $159.45.

A number of equities research analysts recently commented on ILMN shares. Morgan Stanley decreased their price objective on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 11th. Piper Sandler boosted their target price on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Royal Bank of Canada cut their price target on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. UBS Group boosted their price objective on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and cut their target price for the stock from $177.00 to $140.00 in a report on Friday, February 7th.

Illumina Stock Down 5.6 %

Shares of NASDAQ ILMN opened at $97.20 on Friday. Illumina has a 1 year low of $95.23 and a 1 year high of $156.66. The firm’s 50-day moving average is $128.97 and its 200-day moving average is $134.16. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $15.40 billion, a PE ratio of -12.66, a price-to-earnings-growth ratio of 1.67 and a beta of 1.10.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities analysts expect that Illumina will post 4.51 EPS for the current year.

Hedge Funds Weigh In On Illumina

Hedge funds have recently made changes to their positions in the business. Versant Capital Management Inc boosted its holdings in Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 146 shares during the last quarter. Golden State Wealth Management LLC acquired a new position in shares of Illumina during the 4th quarter worth about $32,000. Fourth Dimension Wealth LLC acquired a new stake in shares of Illumina in the fourth quarter valued at about $40,000. Assetmark Inc. raised its holdings in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after acquiring an additional 296 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new position in Illumina during the fourth quarter valued at approximately $45,000. 89.42% of the stock is owned by institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.